Keryx Biopharma (KERX) Misses Q2 EPS by 59c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. ORCL

Go back to Keryx Biopharma (KERX) Misses Q2 EPS by 59c

Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance

July 27, 2017 7:01 AM EDT

Company reported $15.1 million in second quarter 2017 total revenues, including net U.S. Auryxia® (ferric citrate) product sales of $14.1 million, a 71 percent increase compared to the second quarter of 2016 Full year 2017 net U.S Auryxia product sales guidance increased to $62 to $66 million

BOSTON, July 27, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced its financial results for the quarter ended June 30, 2017. The company also reviewed its commercial progress with Auryxia and upcoming milestones.

... More